Cyklokapron Indication:

For use in patients with hemophilia for short term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction.

Cyklokapron Mechanism Of Action:

Tranexamic acid competitively inhibits activation of plasminogen (via binding to the kringle domain), thereby reducing conversion of plasminogen to plasmin (fibrinolysin), an enzyme that degrades fibrin clots, fibrinogen, and other plasma proteins, including the procoagulant factors V and VIII. Tranexamic acid also directly inhibits plasmin activity, but higher doses are required than are needed to reduce plasmin formation.

Cyklokapron Drug Interactions:

Not Available

Cyklokapron Food Interactions:

Not Available

Cyklokapron Generic Name:


  • Tranexamsaeure
  • tranexmic acid
  • Tranhexamic acid
  • Trans AMCHA
  • trans-Amcha
  • trans-Tranexamic acid
  • trans-4-aminomethylcyclohexane-1-carboxylic acid

Drug Type:

Small Molecule; Approved


Absorption of tranexamic acid after oral administration in humans represents approximately 30 to 50% of the ingested dose and bioavailability is not affected by food intake.

Toxicity (Overdose):

Oral LD50 in mice is >10 gm/kg. Symptoms of overdosage may be nausea, vomiting, orthostatic symptoms and/or hypotension.

Protein Binding:

The plasma protein binding of tranexamic acid is about 3% at therapeutic plasma levels and seems to be fully accounted for by its binding to plasminogen (does not bind serum albumin).


Only a small fraction of the drug is metabolized (less than 5%).

Half Life:

Biological half-life in the joint fluid is about 3 hours.

Dosage Forms of Cyklokapron:

Solution Intravenous
Tablet Oral

Chemical IUPAC Name:

4-(aminomethyl)cyclohexane-1-carboxylic acid

Organisms Affected:

Humans and other mammals

Cyklokapron to general, pharmacology

General, pharmacology..